Drug Profile
Colestilan - 3SBio
Alternative Names: SSS 21Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Shandong Chengchuang Pharmaceutical R&D
- Developer 3SBio
- Class Antihyperlipidaemics; Imidazolines; Polymers; Small molecules
- Mechanism of Action Bile acid binding protein modulators; Phosphate binding protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hypercholesterolaemia; Hyperphosphataemia
Most Recent Events
- 29 Aug 2023 Discontinued - Preclinical for Hypercholesterolaemia in China (unspecified route)
- 29 Aug 2023 Discontinued - Preclinical for Hyperphosphataemia in China (unspecified route)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Hypercholesterolaemia in China